DNA RNA and Cells
10 December 2013
Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma10 December 2013
ProNAi Therapeutics Reports Anti-Tumor Activity from Ongoing Phase II Clinical Study of PNT2258, a Novel BCL2-Inhibitor, at ASH Annual Meetin9 December 2013
Interim Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in CLL and MM Studies8 December 2013
Research Study of T Cell Immunotherapy Continues to Show Highly Promising Results in Children and Adults with Leukemia7 December 2013
ZIOPHARM Reports Positive Interim Results in Patients With Advanced Melanoma From Ongoing Phase 1/2 Study of Ad-RTS-IL-124 December 2013
Idera Pharmaceuticals Opens Enrollment for Phase 1/2 Clinical Trial of IMO-8400 in Waldenström’s Macroglobulinemia4 December 2013
Mesoblast Reports Positive Type 2 Diabetes Trial Results26 November 2013
Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-GSK3 Rx and Earns $3 Million Milestone Payment From GSK26 November 2013
BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment25 November 2013
Arrowhead Submits Application to Begin Phase 2a Trial of ARC-520 for the Treatment of Chronic Hepatitis B Infection22 November 2013
Isis Pharmaceuticals to Investigate a Higher Dose of ISIS-SMN Rx in Children with Spinal Muscular Atrophy21 November 2013
Oncolytics Biotech® Inc. Announces Positive Top-Line Data from REO 018 Randomized Study of REOLYSIN® in Head and Neck Cancers19 November 2013
Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma19 November 2013
Mesoblast’s Cell Therapy Strengthens Native Heart Function In Patients With End-Stage Heart Failure on Assisted Circulatory Support18 November 2013
Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for Cardiovascular Disease at American Heart Association Meeting18 November 2013
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIRNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports